$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

2020-02-20

2023-12-31

2024-04-30

40

Study Overview

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

This is a single arm study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy for patients with relapsed/refractory CEA+ Cancer,and obtain the recommended dose and infusion plan.

CEA is a classic tumor marker, especially in more than 80% of colorectal cancer patients. In normal tissue cells, only a small amount of CEA is expressed in the cell membrane of the digestive tract cells, and the CEA is expressed toward the cell cavity under physiological conditions to avoid recognition by CAR-T cells targeting CEA. This is a study to evaluate the efficacy and safety of CEA-targeted CAR-T cells therapy,and obtain the recommended dose and infusion plan.

  • Solid Tumor
  • Lung Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Gastric Cancer
  • Breast Cancer
  • BIOLOGICAL: CEA CAR-T cells
  • PBC017

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2020-04-14  

N/A  

2023-04-16  

2020-04-14  

N/A  

2023-04-18  

2020-04-16  

N/A  

2022-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: CEA+ CAR-T

CAR-T cell reinfusion is carried out in 1~3 times

BIOLOGICAL: CEA CAR-T cells

  • CEA-CAR-T cells will be administered intravenously.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Adverse events that related to treatmentTherapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)2 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
The response rate of CEA CAR-T treatment in patients with relapse/refractory CEA+ Cancer that treatment by CEA CAR-T cells therapyThe response rate of CEA CAR-T treatment will be recorded and assessed according to the irRECIST Version 1.16 months
Duration of Response (DOR) of CEA CAR-T treatment in patients with refractory/relapsed CEA+ CancerDOR will be assessed from the first assessment of CR/PR/SD to the first assessment of recurrence or progression of the disease or death from any cause2 years
Progress-free survival(PFS) of CEA CAR-T treatment in patients with refractory/relapsed CEA+ CancerPFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression2 years
Overall survival(OS) of CEA CAR-T treatment in patients with refractory/relapsed CEA+ CancerOS will be assessed from the first CAR-T cell infusion to death from any cause2 years
Levels of CEA in SerumIn vivo (Serum) quantity of CEA2 years
Rate of CEA CAR-T cells in peripheral bloodIn vivo (peripheral blood) rate of CEA CAR-T cells were determined by means of flow cytometry2 years
Quantity of CEA CAR copies in peripheral bloodIn vivo (peripheral blood) quantity of CEA CAR copies were determined by means of qPCR2 years
Levels of IL-6 in SerumIn vivo (Serum) quantity of IL-63 months
Levels of CRP in SerumIn vivo (Serum) quantity of CRP3 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Zhi Yang, PhD

Phone Number: 86-13206140093

Email: yangzhi@precision-biotech.com

Study Contact Backup

Name: Yingzi Zhang

Phone Number: 86-18623351275

Email: yingzi6526@163.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. No gender limitation, age 18-75 years old (including boundary value); 2. Late, metastatic, or recurrent malignant tumors that have received at least first-line standard treatment failure (progressive or intolerable disease, such as surgery, chemotherapy, radiotherapy, targeted therapy, etc.) or lack effective treatment, and the tumor CEA positive expression (tumor CEA positive or serum CEA level> 50ng / ml confirmed by histology or pathology); 3. There are measurable and assessable lesions: the diameter of the lesion under CT or MRI scan is greater than 0.5cm; 4. The expected survival time is more than 12 weeks; 5. KPS≥60 ; 6. No serious mental disorders; 7. The functions of important organs are basically normal:
    1. Blood routine: white blood cells> 2.0 × 10^9 / L, neutrophils> 0.8 × 10^9 / L, lymphocytes> 0.5 × 10^9 / L, platelets> 50 × 10^9 / L, hemoglobin> 90g / L; 2. Cardiac function: cardiac ultrasound indicates that the cardiac ejection fraction is ≥50%, and there is no obvious abnormality on the electrocardiogram; 3. Renal function: serum creatinine and urea nitrogen ≤3.0 × ULN; 4. Liver function: ALT and AST ≤5.0 × ULN; total bilirubin ≤3.0 × ULN; 5. Blood oxygen saturation> 92%. 8. There are no other serious diseases that conflict with this plan (such as autoimmune diseases, immunodeficiency, organ transplantation); 9. There are no contraindications for apheresis or intravenous blood collection or other cell collection; 10. The patient or his guardian agrees to participate in this clinical trial and sign the ICF, indicating that he understands the purpose and procedures of this clinical trial and is willing to participate in the study.
    Exclusion Criteria:
    1. Have received CAR-T treatment or other genetically modified cell treatment before screening; 2. Participated in other clinical studies within 1 month before screening; 3. Received the following anti-tumor treatment before screening: received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except for those who have confirmed disease progression after treatment; 4. Have received live attenuated vaccine within 4 weeks before screening; 5. Cerebrovascular accident or seizure occurred within 6 months before signing the ICF; 6. Suffering from any of the following heart diseases:
    1. New York Heart Association (NYHA) stage III or IV congestive heart failure; 2. Myocardial infarction occurred or received coronary artery bypass graft (CABG) ≤6 months before enrollment; 3. Clinically significant ventricular arrhythmias, or history of syncope of unknown cause (except for conditions caused by vasovagal or dehydration); 4. Severe cardiac insufficiency, severe heart valve disease and other cardiovascular system diseases; 7. There are active infections or uncontrollable infections requiring systemic treatment within 2 weeks before screening; 8. Active autoimmune diseases; 9. Suffering from chronic enteritis and / or intestinal obstruction; 10. Suffering from other malignant tumors, in addition to fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection; 11. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive; 12. Women who are pregnant or breastfeeding; 13. The situation that other researchers think is not suitable for participating in the study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate